Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on May 13, 2025
Intuitive Machines Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 13, 2025
HOUSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), a leading space technology and infrastructure services company, today announced its financial results for the first quarter ended …
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
GlobeNewswire
·
May 13, 2025
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“ …
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
GlobeNewswire
·
May 13, 2025
YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is …
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
GlobeNewswire
·
May 13, 2025
- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic …
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
GlobeNewswire
·
May 13, 2025
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 13, 2025
- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter from sales and collaborative research agreement – - …
Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
GlobeNewswire
·
May 13, 2025
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. …
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
GlobeNewswire
·
May 13, 2025
Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for …
Cytokinetics Announces Positive Topline Results From MAPLE-HCM
GlobeNewswire
·
May 13, 2025
Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, …
Trace One and Connecting Food Partner to Bring Real-Time Transparency to Global Food Supply Chains
GlobeNewswire
·
May 13, 2025
PARIS, May 13, 2025 (GLOBE NEWSWIRE) -- Trace One, a premier SaaS leader in Product Lifecycle Management (PLM) and compliance software tailored to the food …
Blockchain Futurist Conference Releases Final Schedule
GlobeNewswire
·
May 13, 2025
Toronto, May 13, 2025 (GLOBE NEWSWIRE) -- Blockchain Futurist Conference, Canada’s largest and longest-running Web3 event, today released the final schedule for its seventh annual edition, taking place at the Historic Old Toronto Stock Exchange on May 13, …
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
GlobeNewswire
·
May 13, 2025
PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
May 13, 2025
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Company to hold webcast …
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
GlobeNewswire
·
May 13, 2025
WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in …
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
May 13, 2025
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene …
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
GlobeNewswire
·
May 13, 2025
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo- …
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 13, 2025
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with …
Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025
GlobeNewswire
·
May 13, 2025
LENMELDY™ is the first and only disease-modifying intravenous infusion proven to extend life expectancy in pre-symptomatic late infantile (PSLI) patients and mitigate the cognitive and/or physical impact of early-onset MLD Six accepted abstracts at ASGCT …
Bilibili Inc. Announces Repurchase Right Notification for 1.25% Convertible Senior Notes due 2027
GlobeNewswire
·
May 13, 2025
SHANGHAI, May 13, 2025 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (Nasdaq: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it is notifying holders of its 1.25% …
Immatics Announces First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
May 13, 2025
IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026 IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic …